DiagnoSwiss and bioMérieux to development and use DiagnoSwiss electrochemical microchips in human in vitro diagnostics

28-Jul-2005

bioMérieux and DiagnoSwiss announced that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.

The agreement is restricted to the commercialization and use of DiagnoSwiss' technology in immunoassays and biochemical testing, and is accompanied by a collaboration contract to jointly develop these microsystems into a new generation of analytical platform for clinical applications.

"Through this deal with bioMérieux, we have found the strategic partnership we were expecting for the implementation of our microchip technology in human in vitro diagnostics", said Frédéric Reymond, general manager and co-founder of DiagnoSwiss. "The outstanding expertise of bioMérieux in clinical assays and its strong know-how in instrumentation, industrialization and marketing are major assets to develop our miniaturized tests into a very valuable platform for medical laboratory professionals as well as for physicians and patients. We are confident that this agreement with bioMérieux will enable the integration of our microchips into highly competitive innovative tools in clinical diagnostics. This license confirms the quality of our technology which is intended to be further applied by DiagnoSwiss in food testing and pharmaceutical research".

"This agreement fits perfectly with our objective of reinforcing our position in the field of micro and nanotechnologies. It may lead to the future development of a new generation of highly miniaturized platforms, responding to market demand, notably in the field of immunoassays" adds Benoît Adelus, Executive Vice President of bioMérieux.

DiagnoSwiss' microchips reduce sample and reagent consumption and provide results in a very short time compared to conventional methods. Under the terms of the agreement, these microchips are developed for immunoassays and biochemical tests that are the most widely used classes of analyses performed in clinical diagnostics. They provide an essential aid to the physician for the diagnosis and monitoring of infectious diseases and numerous pathologies such as cancers, cardiovascular diseases or infections caused by an external microorganism (bacterium, virus or parasite ...) such as HIV or hepatitis virus.

https://www.bionity.com/en/news/47922/diagnoswiss-and-biomerieux-to-development-and-use-diagnoswiss-electrochemical-microchips-in-human-in-vitro-diagnostics.html